Withaferin A to prevent GVHD after stem cell transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a natural compound called Withaferin A (from ashwagandha) to see if it helps prevent graft-versus-host disease (GVHD) after a stem cell transplant. The goal is to reduce the risk of transplant complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are generally well enough to do daily activities (ECOG score 0 or 1).
- Your liver, kidneys, and heart are working normally.
- If you can become pregnant, you have a negative pregnancy test within 7 days and agree to use birth control.
- You do not have a serious active infection.
- You have no known allergy to Withaferin A.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a plant-based medicine, Withaferin-A, in people whose graft-versus-host disease (GVHD) after a stem cell transplant has not responded to steroid treatment. GVHD is a condition where donated immune cells attack the body; this study aims to see if Withaferin-A can help control it.
This trial tests whether a probiotic called Bacillus coagulans can help prevent or treat acute graft-versus-host disease, a common complication after donor stem cell transplants. It is for adults with blood cancers or severe aplastic anemia who received a specific type of transplant conditioning.
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
This trial tests whether giving a special type of immune-regulating cells (iMSCs) can help prevent a serious complication called graft-versus-host disease (GvHD) after a stem cell transplant. It’s for people who are at higher risk of developing GvHD based on a blood test taken a week or two after their transplant.
This trial tests two different medicines (ATG-thymoglobulin and ATLG-grafalon) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for older adults with certain blood cancers who have a matched unrelated donor.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
Hear when a new GVHD - Graft-Versus-Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.